1 Ocak 2022 Dergi makalesi Açık Erişim

Ekinci, Meliha; Santos-Oliveira, Ralph; Ilem-Ozdemir, Derya

DataCite XML

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://aperta.ulakbim.gov.tr/record/256299</identifier>
  <creators>
    <creator>
      <creatorName>Ekinci, Meliha</creatorName>
      <givenName>Meliha</givenName>
      <familyName>Ekinci</familyName>
      <affiliation>Ege Univ, Fac Pharm, Dept Radiopharm, TR-35040 Izmir, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Santos-Oliveira, Ralph</creatorName>
      <givenName>Ralph</givenName>
      <familyName>Santos-Oliveira</familyName>
    </creator>
    <creator>
      <creatorName>Ilem-Ozdemir, Derya</creatorName>
      <givenName>Derya</givenName>
      <familyName>Ilem-Ozdemir</familyName>
      <affiliation>Ege Univ, Fac Pharm, Dept Radiopharm, TR-35040 Izmir, Turkey</affiliation>
    </creator>
  </creators>
  <titles>
    <title>Biodistribution Of Tc-99M-Pla/Pva/Atezolizumab Nanoparticles For Non-Small Cell Lung Cancer Diagnosis</title>
  </titles>
  <publisher>Aperta</publisher>
  <publicationYear>2022</publicationYear>
  <dates>
    <date dateType="Issued">2022-01-01</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://aperta.ulakbim.gov.tr/record/256299</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.1016/j.ejpb.2022.05.006</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="http://www.opendefinition.org/licenses/cc-by">Creative Commons Attribution</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">Lung cancer (LC) is a common type of cancer, which is a leading cause of death around the world. There is an urgency for the development of new drugs that could diagnose the LC in the early stages and in a precise manner. In this direction, the development of nanoparticles radiolabeled with the diagnostic radioisotopes represent an important advance in the field of cancer imaging. In this study were developed PLA/PVA/Atezolizumab nano particles which were radiolabeled with 99mTc (Technetium-99m). The radiolabeled nanoparticles were evaluated in both: in-vitro (L-929 and A-549) as in-vivo (mice). The results showed no cytotoxicity effect in the healthy cells (L-929) and cytotoxicity effect in the tumor cells (A-549). The biodistribution assay demonstrated that 99mTc-PLA/PVA/Atezolizumab could reach the tumor site 14-folds higher than the nonparticulate atezolizumab. In conclusion, 99mTc-PLA/PVA/Atezolizumab nanoparticles showed to be a new drug which is able to precisely image the lung tumor, and it must be considered for clinical trials.</description>
  </descriptions>
</resource>